乙型肝炎病毒母婴传播阻断效果研究

目的 为探讨我院实施两种不同方式进行母婴传播阻断的效果.方法 选取乙肝表面抗原阳性或乙肝e抗原和乙肝核心抗体(抗-HBC)阳性的母亲,将单用乙肝疫苗组分为对照组(102例),将孕期加用乙肝高效价免疫球蛋白(HBIG)产后联合使用乙肝疫苗组为治疗组(123例),并对两组的新生儿乙肝表面标志物进行随访一年.结果 对照组12月龄抗-HBs阳性率为86.27%,HBsAg阳性率12.7%,宫内感染率51.9%,免疫失败率22.6%;治疗组12月龄抗-HBs阳性率为96%,HBsAg阳性率4.06%,宫内感染率31.7%,免疫失败率12.8%.两组各项指标差异均有显著意义(P＜0.05).结论 乙肝疫苗联合孕期使用乙肝高效价免疫球蛋白(HBIG)可有效阻断乙肝病毒的母婴传播,值得推广.

Study On Protective Efficacy of HBIG Combining With HBsAg Vaccine in Blocking Mother-Infant Transmission of Hepatitis B Virus

Objective This study was to investigate the preventive efficacy of HBIG combining with HBsAg Vaccine in Bloking Mother-Infant Transmission of Hepatitis B Virus; Methods 225 infants, whose mother with hepatitis B surface antigen (HBsAg) carrier, were divided into 2 group, HBvac 30ug was given at 0,1,6 month in control group, while at pregnancy and birth combining with HBIG 200IU in caring group, serum HBsAg was followed up for one year. Results chronicity of HBsAg in children with HBsAg positive at birth decreased And the incidence of chronic HBSAg infection deceased from 12.7% to 4.06%, compared to caring group in I year(P<0.05). Conclusions combing therapy of HBIG and HBvac may interrupt maternal-infantive transmission and decrease the chronic HBSAg infection. It should be pay close attention to whole society.